Literature DB >> 27697464

Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum.

Simon J de Veer1, Laetitia Furio2, Joakim E Swedberg3, Christopher A Munro4, Maria Brattsand5, Judith A Clements6, Alain Hovnanian7, Jonathan M Harris8.   

Abstract

Proteases have pivotal roles in the skin's outermost layer, the epidermis. In the stratum corneum, serine proteases from the kallikrein-related peptidase (KLK) family have been implicated in several key homeostatic processes, including desquamation. However, the precise contribution of specific KLKs to each process remains unclear. To address this, we used a chemical biology approach and designed selective substrates and inhibitors for KLK7, the most abundant KLK protease in the stratum corneum. The resulting KLK7 inhibitor is the most potent inhibitor of this protease reported to date (Ki = 140 pM), and displays at least 1,000-fold selectivity over several proteases that are related by function (KLK5 and KLK14) or specificity (chymotrypsin). We then used substrates and inhibitors for KLK5, KLK7, and KLK14 to explore the activity of each protease in the stratum corneum using casein zymography and an ex vivo desquamation assay. These experiments provide the most detailed assessment of each KLK's contribution to corneocyte shedding in the plantar stratum corneum, revealing that inhibition of KLK7 alone is sufficient to block shedding, whereas KLK5 is also a major contributor. Collectively, these findings unveil chemical tools for studying KLK activity and demonstrate their potential for characterizing KLK biological functions in epidermal homeostasis.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27697464     DOI: 10.1016/j.jid.2016.09.017

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  11 in total

1.  Bioinformatic analysis identifies epidermal development genes that contribute to melanoma progression.

Authors:  Gastón Barbero; María Victoria Castro; María Josefina Quezada; Pablo Lopez-Bergami
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

2.  A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.

Authors:  Amiram Sananes; Itay Cohen; Anat Shahar; Alexandra Hockla; Elena De Vita; Aubry K Miller; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2018-06-22       Impact factor: 5.157

3.  A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.

Authors:  Scott Lovell; Leran Zhang; Thomas Kryza; Anna Neodo; Nathalie Bock; Elena De Vita; Elizabeth D Williams; Elisabeth Engelsberger; Congyi Xu; Alexander T Bakker; Maria Maneiro; Reiko J Tanaka; Charlotte L Bevan; Judith A Clements; Edward W Tate
Journal:  J Am Chem Soc       Date:  2021-06-04       Impact factor: 16.383

Review 4.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

5.  Mass spectrometry-based determination of Kallikrein-related peptidase 7 (KLK7) cleavage preferences and subsite dependency.

Authors:  Lakmali Munasinghage Silva; Thomas Stoll; Thomas Kryza; Carson Ryan Stephens; Marcus Lachlan Hastie; Helen Frances Irving-Rodgers; Ying Dong; Jeffrey John Gorman; Judith Ann Clements
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

6.  The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer.

Authors:  Thomas Kryza; Nathalie Bock; Scott Lovell; Anja Rockstroh; Melanie L Lehman; Adam Lesner; Janaththani Panchadsaram; Lakmali Munasinghage Silva; Srilakshmi Srinivasan; Cameron E Snell; Elizabeth D Williams; Ladan Fazli; Martin Gleave; Jyotsna Batra; Colleen Nelson; Edward W Tate; Jonathan Harris; John D Hooper; Judith A Clements
Journal:  Mol Oncol       Date:  2019-11-28       Impact factor: 6.603

7.  A Versatile and Robust Serine Protease Inhibitor Scaffold from Actinia tenebrosa.

Authors:  Xingchen Chen; Darren Leahy; Jessica Van Haeften; Perry Hartfield; Peter J Prentis; Chloé A van der Burg; Joachim M Surm; Ana Pavasovic; Bruno Madio; Brett R Hamilton; Glenn F King; Eivind A B Undheim; Maria Brattsand; Jonathan M Harris
Journal:  Mar Drugs       Date:  2019-12-12       Impact factor: 5.118

Review 8.  Bowman-Birk Inhibitors: Insights into Family of Multifunctional Proteins and Peptides with Potential Therapeutical Applications.

Authors:  Agata Gitlin-Domagalska; Aleksandra Maciejewska; Dawid Dębowski
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-25

9.  Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer.

Authors:  Ritu Pandey; Muhan Zhou; Yuliang Chen; Dalila Darmoul; Conner C Kisiel; Valentine N Nfonsam; Natalia A Ignatenko
Journal:  Genes (Basel)       Date:  2021-05-16       Impact factor: 4.096

10.  Potent, multi-target serine protease inhibition achieved by a simplified β-sheet motif.

Authors:  Xingchen Chen; Blake T Riley; Simon J de Veer; David E Hoke; Jessica Van Haeften; Darren Leahy; Joakim E Swedberg; Maria Brattsand; Perry J Hartfield; Ashley M Buckle; Jonathan M Harris
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.